Sortilin‐1, Targeted by miR ‐146a, Regulates the Behavior of Non‐Small Cell Lung Cancer
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Xi Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China. Hauptthemen laut MEDLINE: Adaptor Proteins, Vesicular Transport, MicroRNAs, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Inner Mongolia Autonomous Region of China.
Abstract (Originalsprache)
Background
Sortilin‐1 (SORT1) has been implicated in the pathogenesis of various malignancies, but its role in non‐small cell lung cancer (NSCLC) remains to be elucidated.
Methods
Immunohistochemistry was employed to assess the expression of SORT1 in cancerous tissues compared to adjacent non‐cancerous tissues. NSCLC cell lines, including A549, H1299, and PC‐9, underwent treatment with miR‐146a mimics or SORT1 small interfering RNA (siRNA), followed by evaluations of cell viability, migration, invasion, and apoptosis using cell counting kit‐8, transwell assays, and scratch wound assays. Additionally, bioinformatic methods were employed to predict miR‐146a target genes, which were subsequently validated through dual‐luciferase reporter assays.
Results
SORT1 was significantly elevated in NSCLC tissues compared to adjacent non‐cancerous counterparts. Downregulation of SORT1 inhibited proliferation, invasion, migration of tumor cell lines and promoted apoptosis. Moreover, SORT1 was a direct target of miR‐146a. MiR‐146a modulated tumor cell proliferation, migration, invasion, and apoptosis by suppressing SORT1 expression.
Conclusion
These results suggest that miR‐146a plays a critical role in the pathogenesis of NSCLC by targeting SORT1, highlighting its potential as a therapeutic target for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
- Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
- Key Laboratory for Biomarkers, Inner Mongolia Medical University, Hohhot, China.
- School of Medical Laboratory, Tianjin Medical University, Tianjin, China.
- Department of Pathology, Basic Medical College, Inner Mongolia Medical University, Hohhot, China.
- Department of Pathology, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
ORCID-Profile: Wen-Qi Zheng, Zhi-De Hu
Förderung
- Natural Science Foundation of Inner Mongolia Autonomous Region of China
Zitieren
APA
Lin, X., Yan, Z., Hai, L., Niu, Y., Wen, J. X., Zhu, H. Z., Yan, C., Cha, S. N., Yan, L., Zheng, W. Q., Zhang, M., & Hu, Z. D. (2025). Sortilin‐1, Targeted by miR ‐146a, Regulates the Behavior of Non‐Small Cell Lung Cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70129
Vancouver
Lin X, Yan Z, Hai L, Niu Y, Wen JX, Zhu HZ, et al. Sortilin‐1, Targeted by miR ‐146a, Regulates the Behavior of Non‐Small Cell Lung Cancer. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70129
BibTeX
@article{Lin2025,
author = {Lin, Xi and Yan, Zhi and Hai, Ling and Niu, Yan and Wen, Jian-Xun and Zhu, Hong-Zhe and Yan, Cheng and Cha, Su-Na and Yan, Li and Zheng, Wen-Qi and Zhang, Man and Hu, Zhi-De},
title = {Sortilin‐1, Targeted by miR ‐146a, Regulates the Behavior of Non‐Small Cell Lung Cancer},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70129}
}
EUVIMED